TY - JOUR
T1 - Discovery and development of biomarkers of neurological disease
AU - Dunckley, Travis
AU - Coon, Keith D.
AU - Stephan, Dietrich A.
PY - 2005/3/1
Y1 - 2005/3/1
N2 - The identification of clinically relevant biomarkers for neurological diseases poses unique challenges. These include an historical lack of availability of relevant tissues from the site of pathology, relatively poorly matured techniques for disease diagnosis, the complexity and cellular heterogeneity of the brain, and a clear deficiency of models for functional validation of candidate biomarkers. Here, the unique challenges that neurological disorders introduce to biomarker discovery are described and how modern technological advances in genomics, proteomics and metabolomics are overcoming these obstacles and are driving the discovery of novel biomarkers to improve early diagnosis and therapeutic treatment is discussed.
AB - The identification of clinically relevant biomarkers for neurological diseases poses unique challenges. These include an historical lack of availability of relevant tissues from the site of pathology, relatively poorly matured techniques for disease diagnosis, the complexity and cellular heterogeneity of the brain, and a clear deficiency of models for functional validation of candidate biomarkers. Here, the unique challenges that neurological disorders introduce to biomarker discovery are described and how modern technological advances in genomics, proteomics and metabolomics are overcoming these obstacles and are driving the discovery of novel biomarkers to improve early diagnosis and therapeutic treatment is discussed.
UR - http://www.scopus.com/inward/record.url?scp=14644442276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14644442276&partnerID=8YFLogxK
U2 - 10.1016/S1359-6446(04)03353-7
DO - 10.1016/S1359-6446(04)03353-7
M3 - Review article
C2 - 15749281
AN - SCOPUS:14644442276
SN - 1359-6446
VL - 10
SP - 326
EP - 334
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 5
ER -